NM8074 ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
62	Paroxysmal nocturnal hemoglobinuria	3
109	Atypical hemolytic uremic syndrome	1

62. Paroxysmal nocturnal hemoglobinuria

Clinical trials : 292 / Drugs : 151 - (DrugBank : 49) / Drug target genes : 22 - Drug target pathways : 108

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05731050 (ClinicalTrials.gov)	June 2025	1/2/2023	Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)	A Phase II, Open Label, Multi Dose Study of NM8074in Soliris-Treated Subjects With Paroxysmal Noctur ...	PNH - Paroxysmal Nocturnal Hemoglobinuria	Drug: NM8074	NovelMed Therapeutics	NULL	Not yet recruiting	18 Years	65 Years	All	6	Phase 2	NULL
2	NCT05646524 (ClinicalTrials.gov)	November 2023	30/11/2022	Study of Efficacy and Safety of NM8074in Adult PNH Patients Who Are Naive to Complement Inhibitor Th ...	A Phase II, Open-Label Study of NM8074 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)	Paroxysmal Nocturnal Hemoglobinuria	Drug: NM8074	NovelMed Therapeutics	NULL	Not yet recruiting	18 Years	N/A	All	12	Phase 2	NULL
3	NCT05646563 (ClinicalTrials.gov)	September 2023	30/11/2022	Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris	A Phase II, Open-Label Study of NM8074in Soliris®-Treated Patients With Paroxysmal Nocturnal Hemoglo ...	Paroxysmal Nocturnal Hemoglobinuria	Drug: NM8074;Drug: Soliris	NovelMed Therapeutics	NULL	Not yet recruiting	18 Years	N/A	All	12	Phase 2	NULL

Clinical trials : 114 / Drugs : 36 - (DrugBank : 7) / Drug target genes : 3 - Drug target pathways : 11

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05684159 (ClinicalTrials.gov)	June 2024	4/1/2023	Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy	A Phase II, Open-Label Study of NM8074 in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)	aHUS - Atypical Hemolytic Uremic Syndrome	Drug: NM8074	NovelMed Therapeutics	NULL	Not yet recruiting	18 Years	65 Years	All	12	Phase 2	NULL